Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sierra Oncology

Nasdaq:SRRA
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SRRA
Nasdaq
$107M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Sierra Oncology has significant price volatility in the past 3 months.
SRRA Share Price and Events
7 Day Returns
9.5%
NasdaqGM:SRRA
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-85%
NasdaqGM:SRRA
0%
US Biotechs
-11.5%
US Market
SRRA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sierra Oncology (SRRA) 9.5% -17.8% -24.5% -85% -83.2% -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • SRRA underperformed the Biotechs industry which returned 0% over the past year.
  • SRRA underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
SRRA
Industry
5yr Volatility vs Market

Value

 Is Sierra Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sierra Oncology. This is due to cash flow or dividend data being unavailable. The share price is $10.27.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sierra Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sierra Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SRRA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-30.30
NasdaqGM:SRRA Share Price ** NasdaqGM (2020-03-27) in USD $10.27
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sierra Oncology.

NasdaqGM:SRRA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SRRA Share Price ÷ EPS (both in USD)

= 10.27 ÷ -30.30

-0.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sierra Oncology is loss making, we can't compare its value to the US Biotechs industry average.
  • Sierra Oncology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sierra Oncology's expected growth come at a high price?
Raw Data
NasdaqGM:SRRA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
21.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sierra Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sierra Oncology's assets?
Raw Data
NasdaqGM:SRRA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $46.24
NasdaqGM:SRRA Share Price * NasdaqGM (2020-03-27) in USD $10.27
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:SRRA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SRRA Share Price ÷ Book Value per Share (both in USD)

= 10.27 ÷ 46.24

0.22x

* Primary Listing of Sierra Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sierra Oncology is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Sierra Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sierra Oncology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sierra Oncology expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sierra Oncology expected to grow at an attractive rate?
  • Unable to compare Sierra Oncology's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Sierra Oncology's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Sierra Oncology's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SRRA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SRRA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 21.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SRRA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SRRA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 176 13 -15 2
2023-12-31 86 -8 -48 2
2022-12-31 0 -33 -66 2
2021-12-31 0 -63 -72 2
2020-12-31 0 -60 -72 2
2020-03-28
NasdaqGM:SRRA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -51 -88
2019-09-30 -49 -55
2019-06-30 -52 -58
2019-03-31 -48 -55
2018-12-31 -45 -53
2018-09-30 -43 -50
2018-06-30 -37 -44
2018-03-31 -37 -42
2017-12-31 -36 -42
2017-09-30 -42 -41
2017-06-30 -41 -46
2017-03-31 -43 -48

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sierra Oncology is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Sierra Oncology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SRRA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Sierra Oncology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SRRA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.82 -1.82 -1.82 1.00
2023-12-31 -4.31 -4.31 -4.31 1.00
2022-12-31 -4.82 -4.78 -4.85 2.00
2021-12-31 -6.13 -5.71 -6.55 2.00
2020-12-31 -8.94 -6.89 -10.99 2.00
2020-03-28
NasdaqGM:SRRA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -30.30
2019-09-30 -29.56
2019-06-30 -31.01
2019-03-31 -29.47
2018-12-31 -30.16
2018-09-30 -30.45
2018-06-30 -29.53
2018-03-31 -31.34
2017-12-31 -33.68
2017-09-30 -36.63
2017-06-30 -47.17
2017-03-31 -58.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sierra Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sierra Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sierra Oncology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sierra Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sierra Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sierra Oncology does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sierra Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sierra Oncology's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sierra Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sierra Oncology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SRRA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -88.28 13.74 53.25
2019-09-30 -55.10 13.60 43.12
2019-06-30 -57.76 13.59 45.92
2019-03-31 -54.84 14.28 42.98
2018-12-31 -53.34 14.34 41.08
2018-09-30 -49.65 13.99 37.54
2018-06-30 -44.08 13.63 32.14
2018-03-31 -42.45 12.74 30.55
2017-12-31 -42.02 12.46 30.16
2017-09-30 -40.66 12.15 28.69
2017-06-30 -45.88 12.33 33.90
2017-03-31 -48.42 12.88 33.02
2016-12-31 -47.87 13.71 31.65
2016-09-30 -50.08 14.19 33.70
2016-06-30 -301.41 13.97 29.27
2016-03-31 -444.67 12.01 27.70
2015-12-31 -453.18 9.47 26.36
2015-09-30 -450.33 7.23 20.43
2015-06-30 -193.34 5.53 14.57
2015-03-31 -87.87 4.45 11.55
2014-12-31 -73.72 3.50 19.08
2013-12-31 -12.55 1.16 2.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sierra Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sierra Oncology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sierra Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sierra Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sierra Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sierra Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sierra Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sierra Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sierra Oncology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sierra Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3501521466879E+18x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sierra Oncology Company Filings, last reported 2 months ago.

NasdaqGM:SRRA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 86.35 0.00 147.53
2019-09-30 58.85 5.01 67.69
2019-06-30 70.47 4.97 78.83
2019-03-31 83.59 4.93 90.91
2018-12-31 94.48 4.89 106.05
2018-09-30 107.07 4.86 116.13
2018-06-30 120.65 0.00 125.43
2018-03-31 130.80 0.00 133.83
2017-12-31 94.73 0.00 100.35
2017-09-30 103.78 0.00 107.82
2017-06-30 112.31 0.00 116.70
2017-03-31 121.13 0.00 125.03
2016-12-31 103.25 0.00 109.01
2016-09-30 110.93 0.00 122.68
2016-06-30 124.77 0.00 130.55
2016-03-31 136.31 0.00 140.87
2015-12-31 145.37 0.00 150.18
2015-09-30 155.56 0.00 157.31
2015-06-30 25.92 0.00 25.83
2015-03-31 26.64 0.00 34.07
2014-12-31 38.37 0.00 39.16
2013-12-31 1.13 0.41 2.43
  • Sierra Oncology's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Sierra Oncology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sierra Oncology has sufficient cash runway for 2.9 years based on current free cash flow.
  • Sierra Oncology has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 17.7% each year.
X
Financial health checks
We assess Sierra Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sierra Oncology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sierra Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sierra Oncology dividends.
If you bought $2,000 of Sierra Oncology shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sierra Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sierra Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SRRA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SRRA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sierra Oncology has not reported any payouts.
  • Unable to verify if Sierra Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sierra Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sierra Oncology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sierra Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sierra Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sierra Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sierra Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nick Glover
COMPENSATION $1,941,689
AGE 50
TENURE AS CEO 5.5 years
CEO Bio

Dr. Nicholas R. Glover, also known as Nick, Ph.D. has been Chief Executive Officer, President and Director of Sierra Oncology, Inc. since September 2014 and provided consulting services from July 2014 to August 2014. Dr. Glover served as the President and Chief Executive Officer of YM BioSciences Inc. from November 2010 to February 2013. Dr. Glover served as the Chief Operating Officer of YM BioSciences Inc. from June 7, 2010 to November 2010. He served as President and Chief Executive Officer of Viventia Biotechnologies Inc. from January 8, 2004 to June 2008. He was responsible for all aspects of biotherapeutic development, including GMP manufacturing and has taken products from discovery, through preclinical development and into global registrational clinical trials, with a specific focus in Oncology. He served as Vice President, Corporate Development of Viventia Biotechnologies Inc. since September 2001 until January 8, 2004. Dr. Glover joined Viventia Biotech Inc., in September 2000 and has had responsibility for all aspects of its business development, including financing, corporate partnering and strategic orientation. Dr. Glover has also served as a consultant in the biotechnology and life sciences industries at various times since 2008. Prior to joining Viventia Biotech Inc., he served as an Investment Manager in MDS Capital Corp., where he had responsibilities included sourcing, negotiating and completed venture capital investments in the biotechnology sector. He has been an Independent Non-Executive Director of MEI Pharma, Inc. since June 11, 2013. He served as a Director of Viventia Biotechnologies Inc. since June 2004. He has been a Director of YM BioSciences Inc. since November 18, 2010. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., an M.Sc. in Chemistry from the University of British Columbia, Canada and a Ph.D. in Chemistry from Simon Fraser University, Canada.

CEO Compensation
  • Nick's compensation has increased whilst company is loss making.
  • Nick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sierra Oncology management team in years:

4.3
Average Tenure
52
Average Age
  • The tenure for the Sierra Oncology management team is about average.
Management Team

Nick Glover

TITLE
President
COMPENSATION
$2M
AGE
50
TENURE
5.5 yrs

Sukhi Jagpal

TITLE
Chief Financial Officer
COMPENSATION
$859K
AGE
45
TENURE
5.1 yrs

Barbara Klencke

TITLE
Chief Development Officer
COMPENSATION
$969K
AGE
62
TENURE
4.8 yrs

Emma McCann

TITLE
Senior Vice President of Operations & Program Management
TENURE
0.1 yrs

Keith Anderson

TITLE
Senior Vice President of Technical Operations
COMPENSATION
$1M
AGE
50
TENURE
4.3 yrs

Diane Gardiner

TITLE
Senior Vice President of Human Resources & Administration
TENURE
3.5 yrs

Wendy Chapman

TITLE
Senior Vice President of Clinical Operations
AGE
54
TENURE
5.5 yrs

Gregg Smith

TITLE
Senior Vice President of Drug Development
TENURE
3.8 yrs

Mark Kowalski

TITLE
Chief Medical Officer
COMPENSATION
$864K
AGE
64
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Sierra Oncology board of directors in years:

2.6
Average Tenure
63
Average Age
  • The average tenure for the Sierra Oncology board of directors is less than 3 years, this suggests a new board.
Board of Directors

Robert Pelzer

TITLE
Independent Chairman
COMPENSATION
$118K
AGE
66
TENURE
0.3 yrs

Nick Glover

TITLE
President
COMPENSATION
$2M
AGE
50
TENURE
5.5 yrs

Jeff Cooper

TITLE
Independent Director
COMPENSATION
$118K
AGE
63
TENURE
4 yrs

Ayad Al-Katib

TITLE
Member of Scientific Advisory Board
TENURE
13.4 yrs

Tony Tolcher

TITLE
Member of Scientific Advisory Board

Bruce Zetter

TITLE
Member of Scientific & Medical Advisory Board

Tim Moore

TITLE
Member of Scientific & Medical Advisory Board

Eric Brown

TITLE
Member of DDR Advisory Committee
TENURE
2.6 yrs

Karlene Cimprich

TITLE
Member of DDR Advisory Committee
TENURE
2.6 yrs

Alan D'Andrea

TITLE
Member of DDR Advisory Committee
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Aug 19 Buy Barbara Klencke Individual 22. Aug 19 23. Aug 19 5,725 $18.00 $100,638
X
Management checks
We assess Sierra Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sierra Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Sierra Oncology, Inc. (NASDAQ:SRRA) A Volatile Stock?

(NASDAQ:SRRA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … If this beta value holds true in the future, Sierra Oncology shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Sierra Oncology has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Did You Manage To Avoid Sierra Oncology's (NASDAQ:SRRA) Devastating 82% Share Price Drop?

It must have been painful to be a Sierra Oncology, Inc. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at. … Sierra Oncology is not the only stock that insiders are buying.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Sierra Oncology, Inc. (NASDAQ:SRRA)?

Check out our latest analysis for Sierra Oncology Sierra Oncology Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when Andrew Allen bought US$108k worth of shares at a price of US$1.64 per share. … NasdaqGM:SRRA Recent Insider Trading, June 12th 2019 Sierra Oncology is not the only stock insiders are buying. … Based on our data, Sierra Oncology insiders have about 1.0% of the stock, worth approximately US$513k.

Simply Wall St -

How Does Sierra Oncology, Inc. (NASDAQ:SRRA) Affect Your Portfolio Volatility?

(NASDAQ:SRRA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility).

Simply Wall St -

Have Insiders Been Buying Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Sierra Oncology, Inc. … In the last twelve months, the biggest single purchase by an insider was when Andrew Allen bought US$108k worth of shares at a price of US$1.64 per share. … That means that an insider was happy to buy shares at around the current price.

Simply Wall St -

Do Directors Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?

Every investor in Sierra Oncology, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that used to be publicly owned tend to have lower insider ownership.

Simply Wall St -

How Sierra Oncology Inc (NASDAQ:SRRA) Can Impact Your Portfolio Volatility

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Breakeven On The Horizon For Sierra Oncology Inc (NASDAQ:SRRA)

Sierra Oncology Inc's (NASDAQ:SRRA):. … Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. … The US$269.75m market-cap posted a loss in its most recent financial year of -US$42.01m and a latest trailing-twelve-month loss of -US$42.45m leading to an even wider gap between loss and breakeven

Simply Wall St -

Company Info

Description

Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. The company is also advancing SRA737, which is being investigated in two Phase 1/2 clinical trials primarily focused on patients with ovarian cancer; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Details
Name: Sierra Oncology, Inc.
SRRA
Exchange: NasdaqGM
Founded: 2003
$106,764,167
10,395,732
Website: http://www.sierraoncology.com
Address: Sierra Oncology, Inc.
885 West Georgia Street,
Suite 2150,
Vancouver,
British Columbia, V6C 3E8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SRRA Common Stock Nasdaq Global Market US USD 16. Jul 2015
DB P7N Common Stock Deutsche Boerse AG DE EUR 16. Jul 2015
LSE 0L6B Common Stock London Stock Exchange GB USD 16. Jul 2015
Number of employees
Current staff
Staff numbers
71
Sierra Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:23
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/04
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.